Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.30 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.30 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399948 | 0.76 | DYRK1A (0.34) | PIK3CAPIK3CDPIK3CBPIK3CGDYRK1A | |
| SCHEMBL25401704 | 0.74 | SNCA (0.38) | SNCACDK2 | |
| Lithium Ion SCHEMBL31705920 | 0.73 | HTR2C (0.34) | PIK3CAPIK3CDPIK3CBPIK3CGDYRK1A | |
| Lithium Ion SCHEMBL31705421 | 0.73 | HTR2C (0.34) | PIK3CAPIK3CDPIK3CBPIK3CGDYRK1A | |
| SCHEMBL25403101 | 0.71 | MAPK1 (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGPDCD1 | |
| SCHEMBL23305873 | 0.71 | SNCA (0.31) | SNCA | |
| SCHEMBL15260158 | 0.70 | PIK3CA (0.39) | PIK3CAPIK3CDPIK3CBPIK3CGDYRK1A | |
| SCHEMBL4763681 | 0.69 | SNCA (0.33) | SNCAPIK3CAPIK3CDPDCD1CD274 | |
| SCHEMBL256074 | 0.69 | SNCA (0.52) | SNCACDK2 | |
| SCHEMBL30908171 | 0.68 | CDC7 (0.53) | PIK3CAPIK3CDCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| WO-2023172957-A1 | THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| WO-2021257857-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | SNCA 3135/4885PIK3CA 178/4885PIK3CD 928/4885 |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | SNCA 3135/4885PIK3CA 178/4885PIK3CD 928/4885 |
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | SNCA 4826/4885PIK3CA 82/4885PIK3CD 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.